脂质体布比卡因与罗哌卡因联合神经周围地塞米松在收肌管阻滞用于全膝关节置换术中的比较:一项随机临床试验
该随机临床试验纳入72例拟行初次单侧全膝关节置换术的患者,比较脂质体布比卡因联合盐酸布比卡因与罗哌卡因联合神经周围地塞米松在收肌管阻滞中的镇痛效果。主要终点为术后48小时活动时中重度疼痛发生率,两组无显著差异(47.2% vs 63.9%;RR 0.71;95%CI 0.43-1.16;P=0.149)。脂质体布比卡因组在24和48小时静息及活动时疼痛评分更低、阿片类药物消耗更少、恢复质量更高,且不良事件无显著差异。
要点
- 术后48小时活动时中重度疼痛发生率脂质体布比卡因组47.2% vs 对照组63.9%,无显著差异(RR 0.71;95%CI 0.43-1.16;P=0.149)。
- 脂质体布比卡因组在24和48小时静息及活动时疼痛评分显著更低,0-24小时和24-48小时阿片类药物消耗更少(均P<0.05)。
- 脂质体布比卡因组在24和48小时恢复质量更优(均P<0.05),不良事件发生率两组无显著差异(P>0.05)。
核心结论
- 单次注射收肌管阻滞使用脂质体布比卡因联合盐酸布比卡因,与罗哌卡因联合神经周围地塞米松相比,未显著降低全膝关节置换术后活动时中重度疼痛发生率。
- 但该干预显著降低疼痛强度评分、减少阿片类药物消耗并提高恢复质量,且不增加不良事件。
研究设计与样本
- 前瞻性随机对照试验,纳入72例拟行初次单侧全膝关节置换术的患者,随机分为脂质体布比卡因联合盐酸布比卡因组(n=36)和罗哌卡因联合神经周围地塞米松对照组(n=36)。
- 主要终点为术后48小时活动时中重度疼痛发生率;次要结局包括其他时间点静息和活动时中重度疼痛发生率、数字评定量表疼痛评分、阿片类药物消耗、术后恢复质量和不良事件。
主要发现
- 术后48小时活动时中重度疼痛发生率脂质体布比卡因组47.2% vs 对照组63.9%(相对风险0.71;95%置信区间0.43至1.16;P=0.149)。
- 脂质体布比卡因组在24和48小时静息及活动时数字评定量表评分显著更低(均P<0.05)。
- 脂质体布比卡因组0至24小时和24至48小时阿片类药物消耗更少(均P<0.05)。
- 脂质体布比卡因组在24和48小时恢复质量优于对照组(均P<0.05)。
- 两组不良事件发生率无显著差异(P>0.05)。
关键数值与推荐
- 术后48小时活动时中重度疼痛发生率:脂质体布比卡因组47.2% vs 对照组63.9%,相对风险0.71(95%置信区间0.43至1.16;P=0.149),未达统计学显著。
- 脂质体布比卡因组在24和48小时静息及活动时数字评定量表评分显著低于对照组(均P<0.05)。
- 脂质体布比卡因组0至24小时和24至48小时阿片类药物消耗显著少于对照组(均P<0.05)。
- 脂质体布比卡因组在24和48小时恢复质量显著优于对照组(均P<0.05)。
- 两组不良事件发生率无显著差异(P>0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adductor canal block (ACB) provides effective analgesia for knee surgery while preserving quadriceps muscle strength. However, conventional local anesthetics yield only a short-lasting effect. To extend analgesia duration and reduce opioid usage, the administration of liposomal bupivacaine and perineural dexamethasone has been proposed. The present study assessed and compared the analgesic effectiveness and duration between liposomal bupivacaine and ropivacaine with perineural dexamethasone in patients undergoing total knee arthroplasty (TKA). METHODS: A total of 72 patients scheduled for primary unilateral TKA were prospectively randomized to receive a single-injection ACB with either liposomal bupivacaine combined with bupivacaine hydrochloride (n = 36) or ropivacaine with perineural dexamethasone (control group, n = 36). The primary endpoint was the incidence of moderate-to-severe pain with movement at 48 hours postoperatively. The secondary outcomes included the incidence of moderate-to-severe pain both at rest and with movement at other time points, numerical rating scale pain score, opioid consumption, quality of postoperative recovery, and adverse events. RESULTS: At 48 hours, the incidence of moderate-to-severe pain with movement did not differ between the liposomal bupivacaine group and the control group (47.2 versus 63.9%; relative risk 0.71; 95% confidence interval: 0.43 to 1.16; P = 0.149). Patients receiving liposomal bupivacaine showed significantly lower numerical rating scale scores both at rest and with movement at 24 and 48 hours, and consumed less opioid from zero to 24 and 24 to 48 hours (both P < 0.05). Furthermore, these patients showed an improved quality of recovery at 24 and 48 hours compared to the control group (both P < 0.05). The incidence of adverse events did not differ significantly between the two treatment groups (P > 0.05). CONCLUSIONS: A single-injection ACB with liposomal bupivacaine combined with bupivacaine hydrochloride did not significantly reduce the incidence of moderate-to-severe postoperative pain with movement compared to ropivacaine with perineural dexamethasone after TKA. However, this intervention significantly decreased pain intensity scores, lowered opioid consumption, and improved recovery quality without increasing adverse events compared to the control group.
引用
- Liao C, Li J, Hu X, et al. Liposomal Bupivacaine Versus Ropivacaine With Perineural Dexamethasone in Adductor Canal Block for Total Knee Arthroplasty: A Randomized Clinical Trial. J Arthroplasty. 2025. PMID: 41240971. doi:10.1016/j.arth.2025.11.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。